Picroside I NEW
| Price | $50 |
| Package | 20mg |
| Min. Order: | |
| Supply Ability: | 10g |
| Update Time: | 2024-11-19 |
Product Details
| Product Name: Picroside I | CAS No.: 27409-30-9 |
| Purity: 99.43% | Supply Ability: 10g |
| Release date: 2024/11/19 |
Product Introduction
Bioactivity
| Name | Picroside I |
| Description | Picroside I (6'-Cinnamoylcatalpol), a hepatoprotective agent, is reported to be antimicrobial and used against hepatitis B. It has antioxidant, and anti-inflammatory activities, it may be the valuable anti-invasive drug candidates for cancer therapy by suppressing Collagenases and Gelatinases. Picroside I can enhance basic fibroblast growth factor(bFGF)-, staurosporine- or dbc-mitogen-activated protein (MAP)-induced neurite outgrowth from PC12D cells. |
| In vitro | Picroside I and Picroside II caused a concentration-dependent (> 0.1 microM) enhancement of basic fibroblast growth factor (bFGF, 2 ng/ml)-, staurosporine (10 nM)- and dibutyryl cyclic AMP (dbcAMP, 0.3 mM)-induced neurite outgrowth from PC12D cells. Furthermore, picrosides-induced enhancements of the bFGF-action were markedly inhibited by GF109203X (0.1 microM), a protein kinase C inhibitor. The expression of phosphorylated MAP kinase was markedly increased by bFGF (2 ng/ml) and dbcAMP (0.3 mM), whereas that was not enhanced by staurosporine (10 nM). Picrosides had no effect on the phosphorylation of MAP kinase induced by bFGF or dbcAMP and also unaffected it in the presence of staurosporine. These results suggest that Picroside I and Picroside II enhance bFGF-, staurosporine- or dbcAMP-induced neurite outgrowth from PC12D cells, probably by amplifying a down-stream step of MAP kinase in the intracellular MAP kinase-dependent signaling pathway. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Solubility Information | H2O : 10 mg/mL Ethanol : 10 mg/mL DMSO : 55 mg/mL (111.68 mM) |
| Keywords | Inhibitor | STAT | inhibit | Picroside I |
| Inhibitors Related | Stigmasterol | Doxycycline (hyclate) | Nifuroxazide | Astragaloside IV | Balsalazide sodium hydrate | Doxycycline | Edaravone | Glucosamine | Bovine Type II Collagen | CASIN | Diosgenin | Niclosamide olamine |
| Related Compound Libraries | Anti-Tumor Natural Product Library | Traditional Chinese Medicine Monomer Library | Bioactive Compound Library | Selected Plant-Sourced Compound Library | Natural Product Library | Saccharide and Glycoside Natural Product Library | Anti-Inflammatory Traditional Chinese Medicine Compound Library | Natural Product Library for HTS | Bioactive Compounds Library Max | Ancient Chinese Classical Formulas Compound Library |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
| $2500.00/1g |
VIP1Y
|
R&D Scientific Inc.
|
2024-11-28 | |
| $0.00/1kg |
VIP5Y
|
Hebei Yanxi Chemical Co., Ltd.
|
2023-10-16 | |
| $0.00/100mg |
VIP3Y
|
TargetMol Chemicals Inc.
|
2024-10-28 | |
| $1.00/1g |
VIP6Y
|
Career Henan Chemical Co
|
2019-12-18 | |
| $0.00/20mg |
Shanghai Standard Technology Co., Ltd.
|
2019-10-10 |
United States- Since: 2011-01-07
- Address: 36?Washington?Street, Wellesley?Hills
INQUIRY